Waitzkin Responds.

H. Waitzkin

DOI: https://doi.org/10.2105/AJPH.2016.303207

American Journal of Public Health

Abstract:

What problem does this paper attempt to address?

Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial

Julia Ware,Charlotte K. Boughton,Janet M. Allen,Malgorzata E. Wilinska,Sara Hartnell,Ajay Thankamony,Tabitha Randell,Atrayee Ghatak,Rachel E.J. Besser,Daniela Elleri,Nicola Trevelyan,Fiona M. Campbell,Judy Sibayan,Ryan Bailey,Peter Calhoun,Gareth Dunseath,Roman Hovorka,Tabitha Randell,Vreni Verhoeven,Roman Hovorka,Ajay Thankmonay,Carlo Acerini,David Dunger,Charlotte Boughton,Julia Ware,Martin Tauschmann,Rama Lakshman,Janet Allen,Malgorzata Wilinska,Sara Hartnell,Alina Cezar,Nicole Ashcroft,Mirela de Barros Tamarozzi,Meena Murthy,Atrayee Ghatak,Keith Thornborough,Jonathon Mimnagh,Joanne Shakeshaft,Karen Phelan,Rachel Besser,Rebecca Law,Clare Megson,Jane Haest,Alison West,Imogen Stamford,Daniela Elleri,Morag McDonald,Nicola Trevelyan,Helen Dewar,Rachel Brampton,Gabrielle Price,Gillian Crouch,Fiona Campbell,James Yong,Emily Metcalfe,Andrew Cameron,Julia Lawton,David Rankin,Judy Sibayan,Peter Calhoun,Ryan Bailey,Jessica Rusnak,Brian Bugielski,Gareth Dunseath,Stephen Luzio,Elisabeth Northam,John Todd,Stéphane Roze,Eleanor Scott,Tim Jones,Chris Patterson,Peter Adolfsson,John Gregory,Stephen Greene,Jo Blair,Alexia Passmore,

DOI: https://doi.org/10.2337/dc24-0360

2024-06-26

Diabetes Care

Abstract:OBJECTIVE We evaluated the effect of long-term intensive metabolic control with hybrid closed-loop (CL) on residual C-peptide secretion and glucose control compared with standard insulin therapy in youth with type 1 diabetes over 48 months. RESEARCH DESIGN AND METHODS Following the 24-month primary phase of a multicenter, randomized, parallel trial of 96 newly diagnosed youth aged 10 to 16.9 years, participants were invited to an extension phase using treatment allocated at randomization. They continued with hybrid CL using the Cambridge algorithm or standard insulin therapy (control) until 48 months after diagnosis. Analysis was by intention-to-treat. RESULTS At 24 months after diagnosis, 81 participants (mean ± SD age 14 ± 2 years) continued in the extension phase (47 CL, 34 control). There was no difference in fasting C-peptide corrected for fasting glucose at 48 months between groups (CL: 5 ± 9 vs. control: 6 ± 14 pmol/L per mmol/L; mean adjusted difference −2 [95% CI −7, 4; P = 0.54]). Central laboratory HbA1c remained lower in the CL group by 0.9% (10 mmol/mol [95% CI 0.2, 1.5; 3, 17 mmol/mol); P = 0.009). Time in target range of 3.9 to 10.0 mmol/L was 12 percentage points (95% CI 3, 20; P = 0.008) higher in the CL group compared with control. There were 11 severe hypoglycemic events (6 CL, 5 control) and 7 diabetic ketoacidosis events (3 CL, 4 control) during the extension phase. CONCLUSIONS Improved glycemic control was sustained over 48 months after diagnosis with CL insulin delivery compared with standard therapy in youth with type 1 diabetes. This did not appear to confer a protective effect on residual C-peptide secretion.

endocrinology & metabolism
Tobacco use and nasopharyngeal carcinoma in a cohort of us veterans

W. Chow,J. Mclaughlin,Z. Hrubec,J. Nam,W. Blot

DOI: https://doi.org/10.1002/IJC.2910550403

1993-10-21

International Journal of Cancer

Abstract:The risk of nasopharyngeal carcinoma (NPC), a relatively rare neoplasm in the United States, was examined in relation to tobacco use in a cohort of nearly 250,000 US veterans whose mortality experience was followed for 26 years. A total of 48 NPC deaths were identified during the follow‐up period. Current smokers had a nearly 4‐fold increase in risk of NPC compared with non‐users of any tobacco, with risk increasing to 6.4 among those smoking more than 2 packs daily. After adjustment for age and number of cigarettes smoked, risks were inversely associated with age at starting to smoke, with the highest risk observed among those who started smoking before age 15, although no clear trend associated with duration of smoking was observed. Former cigarette smokers had a small excess risk of NPC, but no association was detected for cigar/pipe users. This study adds strong evidence to the increasing literature linking cigarette smoking to NPC.
Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol

Sybil A McAuley,Martin I de Bock,Vijaya Sundararajan,Melissa H Lee,Barbora Paldus,Geoff R Ambler,Leon A Bach,Morton G Burt,Fergus J Cameron,Philip M Clarke,Neale D Cohen,Peter G Colman,Elizabeth A Davis,Jan M Fairchild,Christel Hendrieckx,D Jane Holmes-Walker,Jodie C Horsburgh,Alicia J Jenkins,Joey Kaye,Anthony C Keech,Bruce R King,Kavita Kumareswaran,Richard J MacIsaac,Roland W McCallum,Jennifer A Nicholas,Catriona Sims,Jane Speight,Stephen N Stranks,Steven Trawley,Glenn M Ward,Sara Vogrin,Timothy W Jones,David N O'Neal

DOI: https://doi.org/10.1136/bmjopen-2017-020274

IF: 3.006

2018-06-09

BMJ Open

Abstract:Introduction: Manual determination of insulin dosing largely fails to optimise glucose control in type 1 diabetes. Automated insulin delivery via closed-loop systems has improved glucose control in short-term studies. The objective of the present study is to determine the effectiveness of 6 months' closed-loop compared with manually determined insulin dosing on time-in-target glucose range in adults with type 1 diabetes. Methods and analysis: This open-label, seven-centre, randomised controlled parallel group clinical trial will compare home-based hybrid closed-loop versus standard diabetes therapy in Australia. Adults aged ≥25 years with type 1 diabetes using intensive insulin therapy (via multiple daily injections or insulin pump, total enrolment target n=120) will undertake a run-in period including diabetes and carbohydrate-counting education, clinical optimisation and baseline data collection. Participants will then be randomised 1:1 either to 26 weeks of MiniMed 670G hybrid closed-loop system therapy (Medtronic, Northridge, CA, USA) or continuation of their current diabetes therapy. The hybrid closed-loop system delivers insulin automatically to address basal requirements and correct to target glucose level, while bolus doses for meals require user initiation and carbohydrate estimation. Analysis will be intention to treat, with the primary outcome time in continuous glucose monitoring (CGM) target range (3.9-10.0 mmol/L) during the final 3 weeks of intervention. Secondary outcomes include: other CGM parameters, HbA1c, severe hypoglycaemia, psychosocial well-being, sleep, cognition, electrocardiography, costs, quality of life, biomarkers of vascular health and hybrid closed-loop system performance. Semistructured interviews will assess the expectations and experiences of a subgroup of hybrid closed-loop users. Ethics and dissemination: The study has Human Research Ethics Committee approval. The study will be conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. Results will be disseminated at scientific conferences and via peer-reviewed publications. Trial registration number: ACTRN12617000520336; Pre-results.
Study protocol for a randomised open-label clinical trial examining the safety and efficacy of the Android Artificial Pancreas System (AAPS) with advanced bolus-free features in adults with type 1 diabetes: the 'CLOSE IT (Closed Loop Open SourcE In Type 1 diabetes) trial

Tom Wilkinson,Dunya Tomic,Erin Boyle,David Burren,Yasser Elghattis,Alicia Jenkins,Celeste Keesing,Sonia Middleton,Natalie Nanayakkara,Jonathan Williman,Martin de Bock,Neale D Cohen,Wilkinson,T.,Tomic,D.,Boyle,E.,Burren,D.,Elghattis,Y.,Jenkins,A.,Keesing,C.,Middleton,S.,Nanayakkara,N.,Williman,J.,de Bock,M.,Cohen,N. D.

DOI: https://doi.org/10.1136/bmjopen-2023-078171

IF: 3.006

2024-02-21

BMJ Open

Abstract:Introduction Multiple automated insulin delivery (AID) systems have become commercially available following randomised controlled trials demonstrating benefits in people with type 1 diabetes (T1D). However, their real-world utility may be undermined by user-associated burdens, including the need to carbohydrate count and deliver manual insulin boluses. There is an important need for a 'fully automated closed loop' (FCL) AID system, without manual mealtime boluses. The (Closed Loop Open SourcE In Type 1 diabetes) trial is a randomised trial comparing an FCL AID system to the same system used as a hybrid closed loop (HCL) in people with T1D, in an outpatient setting over an extended time frame. Methods and analysis Randomised, open-label, parallel, non-inferiority trial comparing the Android Artificial Pancreas System (AAPS) AID algorithm used as FCL to the same algorithm used as HCL. Seventy-five participants aged 18–70 will be randomised (1:1) to one of two treatment arms for 12 weeks: (a) FCL—participants will be advised not to bolus for meals and (b) HCL—participants will use the AAPS AID algorithm as HCL with announced meals. The primary outcome is the percentage of time in target sensor glucose range (3.9–10.0 mmol/L). Secondary outcomes include other glycaemic metrics, safety, psychosocial factors, platform performance and user dietary factors. Twenty FCL arm participants will participate in a 4-week extension phase comparing glycaemic and dietary outcomes using NovoRapid (insulin aspart) to Fiasp (insulin aspart and niacinamide). Ethics and dissemination Approvals are by the Alfred Health Ethics Committee (615/22) (Australia) and Health and Disability Ethics Committees (2022 FULL 13832) (New Zealand). Each participant will provide written informed consent. Data protection and confidentiality will be ensured. Study results will be disseminated by publications, conferences and patient advocacy groups. Trial registration numbers ACTRN12622001400752 and ACTRN12622001401741.

medicine, general & internal
Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial

Sybil A. McAuley,Melissa H. Lee,Barbora Paldus,Sara Vogrin,Martin I. de Bock,Mary B. Abraham,Leon A. Bach,Morton G. Burt,Neale D. Cohen,Peter G. Colman,Elizabeth A. Davis,Christel Hendrieckx,D. Jane Holmes-Walker,Joey Kaye,Anthony C. Keech,Kavita Kumareswaran,Richard J. MacIsaac,Roland W. McCallum,Catriona M. Sims,Jane Speight,Stephen N. Stranks,Vijaya Sundararajan,Steven Trawley,Glenn M. Ward,Alicia J. Jenkins,Timothy W. Jones,David N. O’Neal,David N. O’Neal,Sybil A. McAuley,Melissa H. Lee,Barbora Paldus,Catriona M. Sims,Richard J. MacIsaac,Glenn M. Ward,Peter G. Colman,Neale D. Cohen,Leon A. Bach,Kavita Kumareswaran,Stephen N. Stranks,Morton G. Burt,D. Jane Holmes-Walker,Roland W. McCallum,Joey Kaye,Jane Speight,Christel Hendrieckx,Jennifer Halliday,Sienna Russell-Green,Steven Trawley,Alicia J. Jenkins,Andrzej Januszewski,Anthony C. Keech,Sara Vogrin,Vijaya Sundararajan,Hanafi Mohammed Husin,Philip M. Clarke,Timothy W. Jones,Elizabeth A. Davis,Martin I. de Bock,Mary B. Abraham,Geoff R. Ambler,Fergus J. Cameron,Jan M. Fairchild,Bruce R. King,

DOI: https://doi.org/10.2337/dc20-1447

2020-10-14

Diabetes Care

Abstract:OBJECTIVE To investigate glycemic and psychosocial outcomes with hybrid closed-loop (HCL) versus user-determined insulin dosing with multiple daily injections (MDI) or insulin pump (i.e., standard therapy for most adults with type 1 diabetes). RESEARCH DESIGN AND METHODS Adults with type 1 diabetes using MDI or insulin pump without continuous glucose monitoring (CGM) were randomized to 26 weeks of HCL (Medtronic 670G) or continuation of current therapy. The primary outcome was masked CGM time in range (TIR; 70–180 mg/dL) during the final 3 weeks. RESULTS Participants were randomized to HCL (n = 61) or control (n = 59). Baseline mean (SD) age was 44.2 (11.7) years, HbA1c was 7.4% (0.9%) (57 [10] mmol/mol), 53% were women, and 51% used MDI. HCL TIR increased from (baseline) 55% (13%) to (26 weeks) 70% (10%) with the control group unchanged: (baseline) 55% (12%) and (26 weeks) 55% (13%) (difference 15% [95% CI 11, 19]; P < 0.0001). For HCL, HbA1c was lower (median [95% CI] difference −0.4% [−0.6, −0.2]; −4 mmol/mol [−7, −2]; P < 0.0001) and diabetes-specific positive well-being was higher (difference 1.2 [95% CI 0.4, 1.9]; P < 0.0048) without a deterioration in diabetes distress, perceived sleep quality, or cognition. Seventeen (9 device-related) versus 13 serious adverse events occurred in the HCL and control groups, respectively. CONCLUSIONS In adults with type 1 diabetes, 26 weeks of HCL improved TIR, HbA1c, and their sense of satisfaction from managing their diabetes compared with those continuing with user-determined insulin dosing and self-monitoring of blood glucose. For most people living with type 1 diabetes globally, this trial demonstrates that HCL is feasible, acceptable, and advantageous.

endocrinology & metabolism
Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial

Julia Ware,Janet M Allen,Charlotte K Boughton,Malgorzata E Wilinska,Sara Hartnell,Ajay Thankamony,Carine de Beaufort,Fiona M Campbell,Elke Fröhlich-Reiterer,Maria Fritsch,Sabine E Hofer,Thomas M Kapellen,Birgit Rami-Merhar,Martin Tauschmann,Roman Hovorka,KidsAP Consortium,Carlo L Acerini,Klemen Dovc,Gianluca Musolino,Yue Ruan,Nicole Ashcroft,Matthew Haydock,Catherine Hill,Hildegard Jasser-Nitsche,Julia K Mader,Kerstin Faninger,Heike Bartelt,Alena Thiele,Gabriele Berger,Nicole Blauensteiner,Renata Gellai,Katrin Nagl,Sarah Cvach,Sonja Katzenbeisser-Pawlik,Daniela Abt,Anita Malik,Barbara Lanthaler,Matthias Wenzel,Fiona Campbell,James Yong,Emily Metcalfe,Majorie Allen,Sarah Ambler,Saima Waheed,Jane Exall,Joseph Tulip,Ulrike Schierloh,Muriel Fichelle,Dominique Schaeffer,Julia Lawton,David Rankin,Ruth Hart,Barbara Kimbell,Stéphane Roze,Timothy Jones,Chris Patterson,Peter Adolfsson

DOI: https://doi.org/10.2337/dc24-1313

2024-12-01

Diabetes Care

Abstract:Objective: We aimed to evaluate the longer-term safety and efficacy of hybrid closed-loop (CL) therapy in very young children with type 1 diabetes (T1D). Research design and methods: Following a 16-week multinational, randomized crossover trial comparing hybrid CL with sensor-augmented pump (SAP) therapy in 74 very young children aged 1-7 years with T1D, participants were invited to an extension phase using CL for a further 18 months. Outcomes were compared with the primary-phase SAP period and primary-phase CL period. Results: After the primary study phase, 60 participants were eligible to enroll in the extension. Of these, 49 consented (mean ± SD age 6.6 ± 1.5 years) to continue use of CL for 18 months. Percentage time in range (TIR) 3.9-10.0 mmol/L was 8.4 percentage points (95% CI 6.7-10.1; P < 0.001) higher, while HbA1c was 0.4% ([5.0 mmol/mol], 95% CI 0.3-0.6 [3.7-6.2]; P < 0.001) lower during the CL extension phase compared with primary-phase SAP period. At 18 months, mean HbA1c was 6.7 ± 0.5% and TIR was 70 ± 7%, compared with 6.7 ± 0.5% and 71 ± 6% in the primary-phase CL period. Time in hypoglycemia (<3.9 mmol/L) was similar between CL extension phase and both primary-phase SAP (P = 0.31) and CL periods (P = 0.70). There were two severe hypoglycemia events and one other serious adverse event during the extension phase. One unexpected serious adverse device effect occurred. Conclusions: Use of the Cambridge hybrid CL system led to sustained improvements in glycemic control lasting more than 18 months in very young children with T1D.
Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes

Sze May Ng,Neil P. Wright,Diana Yardley,Fiona Campbell,Tabitha Randell,Nicola Trevelyan,Atrayee Ghatak,Peter C. Hindmarsh

DOI: https://doi.org/10.1186/s12916-024-03396-x

IF: 9.3

2024-04-27

BMC Medicine

Abstract:Hybrid closed-loop (HCL) systems seamlessly interface continuous glucose monitoring (CGM) with insulin pumps, employing specialised algorithms and user-initiated automated insulin delivery. This study aimed to assess the efficacy of HCLs at 12 months post-initiation on glycated haemoglobin (HbA1c), time-in-range (TIR), hypoglycaemia frequency, and quality of life measures among children and young people (CYP) with type 1 diabetes mellitus (T1DM) and their caregivers in a real-world setting. Conducted between August 1, 2021, and December 10, 2022, the prospective recruitment took place in eight paediatric diabetes centres across England under the National Health Service England's (NHSE) HCL pilot real-world study. A cohort of 251 CYP (58% males, mean age 12.3 years) with T1DM participated (89% white, 3% Asian, 4% black, 3% mixed ethnicity, and 1% other). The study utilised three HCL systems: (1) Tandem Control-IQ AP system, which uses the Tandem t:slim X2 insulin pump (Tandem Diabetes Care, San Diego, CA, USA) with the Dexcom G6® CGM (Dexcom, San Diego, CA, USA) sensor; (2) Medtronic MiniMedTM 780G with the Guardian 4 sensor (Medtronic, Northridge, CA, USA); and (3) the CamAPS FX (CamDiab, Cambridge, UK) with the Ypsomed insulin pump (Ypsomed Ltd, Escrick, UK) and Dexcom G6® CGM.

medicine, general & internal
Neptus - a framework to support multiple vehicle operation

P. Dias,Rui M. F. Gomes,José Pinto,S. L. Fraga,G. Gonçalves,João Borges Sousa,Fernando Lobo Pereira

DOI: https://doi.org/10.1109/OCEANSE.2005.1513187

2005-06-20

Oceans

Abstract:This paper describes the development of a C3I (communications, command, control and intelligence/information) infrastructure, taking place at the Underwater Systems and Technology Laboratory (LSTS) of FEUP. This infrastructure, the Neptus framework, goal is to support the coordinated operation of heterogeneous teams, which include autonomous and remotely operated underwater, surface, land, and air vehicles and people. People perform a fundamental role, not only in the case of remotely operated vehicles, but also with autonomous vehicles where mix-initiative operation is a requirement. The operational scenarios for these teams are mainly environmental monitoring missions but could also include environmental disaster scenarios, rescue missions, etc. The Neptus distributed architecture is service oriented, which enables high degrees of interoperability between applications, of scalability (number of nodes), and of reconfiguration (number and type of nodes).
Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial

Mary B. Abraham,Grant J. Smith,Julie Dart,Antony Clarke,Keely Bebbington,Janice M. Fairchild,Geoffrey R. Ambler,Fergus J. Cameron,Elizabeth A. Davis,Timothy W. Jones

DOI: https://doi.org/10.2337/dc24-0276

2024-09-13

Diabetes Care

Abstract:OBJECTIVE To determine the efficacy of advanced hybrid closed loop (AHCL) therapy in a high-risk cohort of youth on continuous subcutaneous insulin infusion (CSII) ± continuous glucose monitoring (CGM) with suboptimal glycemia. RESEARCH DESIGN AND METHODS In a 6-month multicenter clinical trial, youth with type 1 diabetes with mean and most recent HbA1c > 8.5% (65 mmol/mol) were randomly assigned 1:1 to AHCL or treatment as usual (CSII ± CGM). The primary outcome was the 24-week between-group difference in HbA1c. Secondary outcomes included CGM metrics from masked CGM and psychological measures (youth-reported problem areas in diabetes [PAID], quality of life, anxiety, depression, and hypoglycemia fear) assessed using validated questionnaires. RESULTS A total of 42 participants were randomized (mean [SD] age 16.2 [2.5] years, HbA1c 9.8 [1.1]% or 84 [12] mmol/mol, PAID score 50.3 [19.8]). At study end, the mean (SD) HbA1c was 8.8 (1.1)% or 73 (12) mmol/mol with AHCL and 9.9 (1.2)% or 85 (13.1) mmol/mol with CSII ± CGM, with mean adjusted group difference of −0.77% (95% CI −1.45 to −0.09) or −8.4 mmol/mol (−15.8 to −1.0); P = 0.027. AHCL increased time in range 70–180 mg/dL (difference 19.1%; 95% CI 11.1 to 27.1), reduced time >180 mg/dL (difference −17.7%; 95% CI −26.6 to −8.8), with no increase in time spent <70 mg/dL (difference −0.8%; 95% CI −2.7 to 0.6). There was no evidence for difference in psychosocial outcomes between the two groups at study end. CONCLUSIONS AHCL should be encouraged in youth with suboptimal glycemia, as AHCL improves glycemia. However, psychological support remains vital, as technology alone may not be able to reduce the burden of diabetes care in this subgroup.

endocrinology & metabolism
Effectiveness of a structured educational intervention using psychological delivery methods in children and adolescents with poorly controlled type 1 diabetes: a cluster-randomized controlled trial of the CASCADE intervention

Deborah Christie,Rebecca Thompson,Mary Sawtell,Elizabeth Allen,John Cairns,Felicity Smith,Elizabeth Jamieson,Katrina Hargreaves,Anne Ingold,Lucy Brooks,Meg Wiggins,Sandy Oliver,Rebecca Jones,Diana Elbourne,Andreia Santos,Ian C K Wong,Simon O'Neil,Vicki Strange,Peter Hindmarsh,Francesca Annan,Russell M Viner

DOI: https://doi.org/10.1136/bmjdrc-2015-000165

2016-06-01

Abstract:Introduction: Type 1 diabetes (T1D) in children and adolescents is increasing worldwide with a particular increase in children <5 years. Fewer than 1 in 6 children and adolescents achieve recommended glycated hemoglobin (HbA1c) values. Methods: A pragmatic, cluster-randomized controlled trial assessed the efficacy of a clinic-based structured educational group incorporating psychological approaches to improve long-term glycemic control, quality of life and psychosocial functioning in children and adolescents with T1D. 28 pediatric diabetes services were randomized to deliver the intervention or standard care. 362 children (8-16 years) with HbA1c≥8.5% were recruited. Outcomes were HbA1c at 12 and 24 months, hypoglycemia, admissions, self-management skills, intervention compliance, emotional and behavioral adjustment, and quality of life. A process evaluation collected data from key stakeholder groups in order to evaluate the feasibility of delivering the intervention. Results: 298/362 patients (82.3%) provided HbA1c at 12 months and 284/362 (78.5%) at 24 months. The intervention did not improve HbA1c at 12 months (intervention effect 0.11, 95% CI -0.28 to 0.50, p=0.584), or 24 months (intervention effect 0.03, 95% CI -0.36 to 0.41, p=0.891). There were no significant changes in remaining outcomes. 96/180 (53%) families in the intervention arm attended at least 1 module. The number of modules attended did not affect outcome. Reasons for low uptake included difficulties organizing groups and work and school commitments. Those with highest HbA1cs were less likely to attend. Mean cost of the intervention was £683 per child. Conclusions: Significant challenges in the delivery of a structured education intervention using psychological techniques to enhance engagement and behavior change delivered by diabetes nurses and dietitians in routine clinical practice were found. The intervention did not improve HbA1c in children and adolescents with poor control. Trial registration number: ISRCTN52537669, results.
Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.

D. Junquero,P. Oms,E. Carilla-Durand,J. Autin,J. Tarayre,A. Degryse,J. Patoiseau,F. Colpaert,A. Delhon

DOI: https://doi.org/10.1016/S0006-2952(00)00523-2

IF: 6.1

Biochemical Pharmacology

Abstract:
The JDRF CCTN CGM TIME Trial: Timing of Initiation of continuous glucose Monitoring in Established pediatric type 1 diabetes: study protocol, recruitment and baseline characteristics

Margaret L Lawson,Brenda Bradley,Karen McAssey,Cheril Clarson,Susan E Kirsch,Farid H Mahmud,Jacqueline R Curtis,Christine Richardson,Jennilea Courtney,Tammy Cooper,Cynthia J Downie,Gopalan Rajamannar,Nicholas Barrowman,CGM TIME Trial Study Group,JDRF Canadian Clinical Trial Network CCTN1101,Janice Muileboom,Anne Marie DiGravio,Elizabeth Helden,Amiee Hill,Chantelle Black,Ruth Duncan,Keira Evans,Jenna MacIsaac,Margaret Watson,Alanna Landry,Sameer Datwani,H Mahmud,Lynne Cormack,Kamaljeet Sahota,Vanita Pais,Liz Liddiard,Dildeep Kaur,Melody Chow,Helen Sun,Olivia Lou,Concepcion Nierras,Heather J Dean,William V Tamborlane,Howard A Wolpert

DOI: https://doi.org/10.1186/1471-2431-14-183

2014-07-18

Abstract:Background: Continuous glucose monitoring (CGM) has been shown to improve glucose control in adults with type 1 diabetes. Effectiveness of CGM is directly linked with CGM adherence, which can be challenging to maintain in children and adolescents. We hypothesize that initiating CGM at the same time as starting insulin pump therapy in pump naïve children and adolescents with type 1 diabetes will result in greater CGM adherence and effectiveness compared to delaying CGM introduction by 6 months, and that this is related to greater readiness for making behaviour change at the time of pump initiation. Methods/design: The CGM TIME Trial is a multicenter randomized controlled trial. Eligible children and adolescents (5-18 years) with established type 1 diabetes were randomized to simultaneous initiation of pump (Medtronic Veo©) and CGM (Enlite©) or to standard pump therapy with delayed CGM introduction. Primary outcomes are CGM adherence and hemoglobin A1C at 6 and 12 months post pump initiation. Secondary outcomes include glycemic variability, stage of readiness, and other patient-reported outcomes with follow-up to 24 months. 144 (95%) of the 152 eligible patients were enrolled and randomized. Allowing for 10% withdrawals, this will provide 93% power to detect a between group difference in CGM adherence and 86% power to detect a between group difference in hemoglobin A1C. Baseline characteristics were similar between the treatment groups. Analysis of 12 month primary outcomes will begin in September 2014. Discussion: The CGM TIME Trial is the first study to examine the relationship between timing of CGM initiation, readiness for behaviour change, and subsequent CGM adherence in pump naïve children and adolescents. Its findings will advance our understanding of when and how to initiate CGM in children and adolescents with type 1 diabetes. Trial registration: ClinicalTrial.gov NCT01295788. Registered 14 February 2011.
Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring

Tim van den Heuvel,Ralf Kolassa,Winfried Keuthage,Jens Kroeger,Roseline Ré,Simona de Portu,Linda Vorrink,John Shin,Javier Castañeda,Robert Vigersky,Ohad Cohen

DOI: https://doi.org/10.1177/19322968231161320

2023-03-25

Journal of Diabetes Science and Technology

Abstract:Journal of Diabetes Science and Technology, Ahead of Print. Background:This analysis reports the findings from a predefined exploratory cohort (cohort B) from the ADAPT (ADvanced Hybrid Closed Loop Study in Adult Population with Type 1 Diabetes) study. Adults with type 1 diabetes (T1D) with suboptimal glucose control were randomly allocated to an advanced hybrid closed-loop (AHCL) system or multiple daily injections of insulin (MDI) plus real-time continuous glucose monitoring (RT-CGM).Methods:In this prospective, multicenter, exploratory, open-label, randomized controlled trial, 13 participants using MDI + RT-CGM and with HbA1c ≥8.0% were randomized to switch to AHCL (n = 8) or continue with MDI + RT-CGM (n = 5) for six months. Prespecified endpoints included the between-group difference in mean change from baseline in HbA1c, CGM-derived measures of glycemic control, and safety.Results:The mean HbA1c level decreased by 1.70 percentage points in the AHCL group versus a 0.60 percentage point decrease in the MDI + RT-CGM group, with a model-based treatment effect of −1.08 percentage points (95% confidence interval [CI] = −2.17 to 0.00 percentage points; P = .0508) in favor of AHCL. The percentage of time spent with sensor glucose levels between 70 and 180 mg/dL in the study phase was 73.6% in the AHCL group and 46.4% in the MDI + RT-CGM group; model-based between-group difference of 28.8 percentage points (95% CI = 12.3 to 45.3 percentage points; P = .0035). No diabetic ketoacidosis or severe hypoglycemia occurred in either group.Conclusions:In people with T1D with HbA1c ≥8.0%, the use of AHCL resulted in improved glycemic control relative to MDI + RT-CGM. The scale of improvement suggests that AHCL should be considered as an option for people not achieving good glycemic control on MDI + RT-CGM.
Parental perspectives following the implementation of advanced hybrid closed‐loop therapy in children and adolescents with type 1 diabetes and elevated glycaemia

Sin‐ting Tiffany Lai,Sara E. Styles,Alisa Boucsein,Yongwen Zhou,Venus Michaels,Craig Jefferies,Esko Wilshire,Martin I. De Bock,Benjamin J. Wheeler

DOI: https://doi.org/10.1111/dme.15448

IF: 3.5

2024-11-28

Diabetic Medicine

Abstract:Aims To identify from a parental perspective facilitators and barriers of effective implementation of advanced hybrid closed‐loop (AHCL) therapy in children and adolescents with type 1 diabetes (T1D) with elevated glycaemia. Methods Semi‐structured interviews were conducted with parents of participants while in a post‐trial extension phase of the CO‐PILOT randomized controlled trial. The Capability, Opportunity, Motivation, Behaviour Model and Theoretical Domain Framework informed the interviews and framework analysis. Results Eleven parents of 9 children and adolescents were interviewed. The median age of their children and adolescents was 14.2 years (IQR 13.3–14.7) with median HbA1c 78 mmol/mol (IQR 75–86) (9.3% IQR 9–10) before starting AHCL. Facilitators of implementing AHCL therapy included the following: (1) knowledge acquired from training, (2) establishing routines and action plans, (3) remote glucose monitoring, (4) achievement of glycaemic goals through automation, (5) children/adolescents' capability to use AHCL independently, (6) improved outcomes incentivized continued AHCL, (7) optimism about sustained improvements and (8) social support from healthcare providers, school staff, peers and parents. Barriers to AHCL implementation included the following: (1) challenges with device usability, (2) need for technical support, (3) forgotten knowledge and skills, (4) non‐adherence to best practices, (5) negative social influences, (6) physical and psychosocial burden and (7) negative emotions. Conclusions This study provides comprehensive insights into parental perspectives of influences on implementing AHCL therapy in children and adolescents with elevated glycaemia. As parents remain key partners in diabetes care, these findings inform successful implementation of AHCL and development of future diabetes technology.

endocrinology & metabolism
[An eye wound that led to the death of a king in the wedding of Philip II and Elizabeth of Valois].

C. Gutierrez-Ortiz

DOI: https://doi.org/10.1016/j.oftal.2013.12.012

Archivos de la Sociedad Española de Oftalmología

Abstract:
Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies

Mark Christiansen,Amy Bartee,Amy Lalonde,Richard E Jones,Michelle Katz,Howard Wolpert,Ronald Brazg

DOI: https://doi.org/10.1089/dia.2020.0318

Abstract:Background: Automated insulin delivery (AID) systems have demonstrated improvements in time-in-range (TIR, blood glucose 70-180 mg/dL) without increasing hypoglycemia. Testing a closed-loop system in an inpatient environment with supervised challenges allows for initial evaluation of performance and safety of the system. Methods: Adults with type 1 diabetes (T1D) were enrolled into two similar studies (n = 10 per study), with 3-day inpatient analysis periods. Participants tested a Lilly hybrid closed-loop (HCL) system comprising an investigational insulin pump, insulin lispro, a pump-embedded model predictive control algorithm, a continuous glucose monitor (CGM), and an external dedicated controller. Each protocol included meal-related and exercise challenges to simulate real-world diabetes self-management errors. Only study staff interacted with the HCL system. Performance was assessed using standard CGM metrics overall and within prespecified periods. Results: Participants (25% male) had mean ± standard deviation (SD) age 44.7 ± 14.2 years, T1D duration 30.2 ± 11.1 years, A1C 7.2% ± 0.8%, and insulin usage 0.53 ± 0.21 U/(kg·day). Percentage TIR 70-180 mg/dL (mean ± SD) was 81.2 ± 8.4 overall, 85.2 ± 8.1 outside of challenge periods, 97.3 ± 5.3 during the nocturnal periods, and 74.5 ± 16.2 for the postprandial periods. During challenge periods, percentage TIR for the overbolus challenge was 65.4 ± 29.2 and that for the delayed bolus challenge was 57.1 ± 25.1. No adverse events (AEs), serious AEs, or unanticipated adverse device events occurred while participants were using the HCL system. Conclusions: In participants with T1D, Lilly AID system demonstrated expected algorithm performance and safety with satisfactory glycemic outcomes overall and in response to simulated diabetes management challenges. Additional studies in less supervised conditions and with broader patient populations are warranted. ClinicalTrials.gov Registration number NCT03743285, NCT03849612.
A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes

Barbora Paldus,Dale Morrison,Dessi P Zaharieva,Melissa H Lee,Hannah Jones,Varuni Obeyesekere,Jean Lu,Sara Vogrin,André La Gerche,Sybil A McAuley,Richard J MacIsaac,Alicia J Jenkins,Glenn M Ward,Peter Colman,Carmel E M Smart,Rowen Seckold,Bruce R King,Michael C Riddell,David N O'Neal

DOI: https://doi.org/10.2337/dc21-1593

2022-01-01

Diabetes Care

Abstract:Objective: To compare glucose control with hybrid closed-loop (HCL) when challenged by high intensity exercise (HIE), moderate intensity exercise (MIE), and resistance exercise (RE) while profiling counterregulatory hormones, lactate, ketones, and kinetic data in adults with type 1 diabetes. Research design and methods: This study was an open-label multisite randomized crossover trial. Adults with type 1 diabetes undertook 40 min of HIE, MIE, and RE in random order while using HCL (Medtronic MiniMed 670G) with a temporary target set 2 h prior to and during exercise and 15 g carbohydrates if pre-exercise glucose was <126 mg/dL to prevent hypoglycemia. Primary outcome was median (interquartile range) continuous glucose monitoring time-in-range (TIR; 70-180 mg/dL) for 14 h post-exercise commencement. Accelerometer data and venous glucose, ketones, lactate, and counterregulatory hormones were measured for 280 min post-exercise commencement. Results: Median TIR was 81% (67, 93%), 91% (80, 94%), and 80% (73, 89%) for 0-14 h post-exercise commencement for HIE, MIE, and RE, respectively (n = 30), with no difference between exercise types (MIE vs. HIE; P = 0.11, MIE vs. RE, P = 0.11; and HIE vs. RE, P = 0.90). Time-below-range was 0% for all exercise bouts. For HIE and RE compared with MIE, there were greater increases, respectively, in noradrenaline (P = 0.01 and P = 0.004), cortisol (P < 0.001 and P = 0.001), lactate (P ≤ 0.001 and P ≤ 0.001), and heart rate (P = 0.007 and P = 0.015). During HIE compared with MIE, there were greater increases in growth hormone (P = 0.024). Conclusions: Under controlled conditions, HCL provided satisfactory glucose control with no difference between exercise type. Lactate, counterregulatory hormones, and kinetic data differentiate type and intensity of exercise, and their measurement may help inform insulin needs during exercise. However, their potential utility as modulators of insulin dosing will be limited by the pharmacokinetics of subcutaneous insulin delivery.
Automated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1c

Alisa Boucsein,Yongwen Zhou,Venus Michaels,Jillian J Haszard,Craig Jefferies,Esko Wiltshire,Ryan G Paul,Amber Parry-Strong,Maheen Pasha,Goran Petrovski,Martin I de Bock,Benjamin J Wheeler

DOI: https://doi.org/10.1056/EVIDoa2400185

Abstract:Background: Automated insulin delivery is the treatment of choice in adults with type 1 diabetes. Data are needed on the efficacy and safety of automated insulin delivery for children and youth with diabetes and elevated glycated hemoglobin levels. Methods: In this multicenter, open-label randomized controlled trial, we assigned patients with type 1 diabetes in a 1:1 ratio either to use an automated insulin delivery system (MiniMed 780G) or to receive usual diabetes care of multiple daily injections or non--automated pump therapy (control). The patients were children and youth (defined as 7 to 25 years of age) with elevated glycemia (glycated hemoglobin ≥8.5% with no upper limit). The primary outcome was the baseline-adjusted between-group difference in glycated hemoglobin at 13 weeks. Results: A total of 80 patients underwent randomization (37 to automated insulin delivery and 43 to control) and all patients completed the trial. At 13 weeks, the mean (±SD) glycated hemoglobin decreased from 10.5±1.9% to 8.1±1.8% in the automated insulin delivery group but remained relatively consistent in the control group, changing from 10.4±1.6% to 10.6±1.8% (baseline-adjusted between-group difference, -2.5 percentage points; 95% confidence interval [CI], -3.1 to -1.8; P<0.001). Patients in the automated insulin delivery group spent on average 8.4 hours more in the target glucose range of 70 to 180 mg/dl than those in the control group. One severe hypoglycemia event and two diabetic ketoacidosis events occurred in the control group, with no such events in the automated insulin delivery group. Conclusions: In this trial of 80 children and youth with elevated glycated hemoglobin, automated insulin delivery significantly reduced glycated hemoglobin compared with usual diabetes care, without resulting in severe hypoglycemia or diabetic ketoacidosis events. (Funded by Lions Clubs New Zealand District 202F and others; Australian New Zealand Clinical Trials Registry number, ACTRN12622001454763.).
Lived Experience of Fully Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes

Rama Lakshman,Sara Hartnell,Julia Ware,Janet M Allen,Malgorzata E Wilinska,Munachiso Nwokolo,Mark L Evans,Roman Hovorka,Charlotte K Boughton,Janet M. Allen,Malgorzata E. Wilinska,Mark L. Evans,Charlotte K. Boughton

DOI: https://doi.org/10.1089/dia.2023.0394

2024-03-02

Diabetes Technology & Therapeutics

Abstract:Introduction: The Closing the Loop in Adults With Type 1 Diabetes (CLEAR) randomized crossover study compared a novel fully closed-loop insulin delivery system with no carbohydrate entry or mealtime bolusing (CamAPS HX), with standard insulin pump therapy and glucose sensor in adults with type 1 diabetes and suboptimal glycemic outcomes. This qualitative substudy aimed to understand the psychosocial impact of using the fully automated system. Materials and Methods: Adults participating in the CLEAR study were invited to take part in a virtual semistructured interview after they had completed 8 weeks using the fully closed-loop system. Recruitment continued until there was adequate representation and data saturation occurred. Interviews were anonymized and transcribed for in-depth thematic analysis using an inductive-deductive approach. Study participants were also asked to complete questionnaires assessing diabetes distress, hypoglycemia confidence, and closed-loop treatment satisfaction. Results: Eleven participants (eight male and three female; age range 26–66 years) were interviewed. After an initial adjustment period, interviewees reported enjoying a reduction in diabetes burden, freed-up mental capacity, and improved mood. All were happy with overnight glycemic outcomes, with the majority reporting benefits on sleep. Although experiences of postprandial glucose outcomes varied, all found mealtimes easier and less stressful, particularly when eating out. Negatives raised by participants predominantly related to the insulin pump hardware, but some also reported increased snacking and challenges around resuming carbohydrate counting at trial closeout. Conclusions: In adults with type 1 diabetes, use of a fully closed-loop insulin delivery system had significant quality-of-life benefits and provided a welcome break from the day-to-day demands of living with diabetes. Clinical Trial Registration: NCT04977908.

endocrinology & metabolism
Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus

Yu Pei,Weijian Ke,Jing Lu,Yi Lin,Zhijian Zhang,Yongde Peng,Yan Bi,Yanbing Li,Jue Hou,Xiaolu Zhang,Xiaoxiao Chen,Yuri Treminio,Scott W. Lee,John Shin,Andrew S. Rhinehart,Robert A. Vigersky,Yiming Mu

DOI: https://doi.org/10.1089/dia.2023.0234

2023-01-01

Diabetes Technology & Therapeutics

Abstract:Background: While evidence supports glycemic control benefits for individuals with type 1 diabetes mellitus (T1DM) using hybrid closed-loop (HCL) systems, HCL automated insulin delivery therapy in China has not been assessed. This study evaluated safety events and effectiveness during HCL system use by Chinese adolescents and adults with T1DM.Methods: Sixty-two participants (n = 12 adolescents with a mean +/- standard deviation [SD] of 15.5 +/- 1.1 years and n = 50 adults [mean +/- SD of 37.6 +/- 11.1 years]) with T1DM and baseline A1C of 7.1% +/- 1.0% underwent a run-in period (similar to 2 weeks) using open-loop Manual Mode (sensor-augmented pump) insulin delivery with the MiniMed (TM) 770G system with the Guardian (TM) Sensor (3) glucose sensor, followed by a study period (4 weeks) with HCL Auto Mode enabled. Analyses compared continuous glucose monitoring data and insulin delivered during the run-in versus study period (Wilcoxon signed-rank test or t-test). Safety events included rates of severe hypoglycemia and diabetic ketoacidosis (DKA).Results: Compared to baseline run-in, overall Auto Mode use increased time in range (TIR, 70-180 mg/dL) from 75.3% to 80.9% (P < 0.001) and reduced time below range (TBR, <70 mg/dL) from 4.7% to 2.2% (P < 0.001). Subgroup analysis demonstrated that participants (n = 29) with baseline A1C <7.0% had TBR that reduced from 5.6% to 2.0%, while participants (n = 21) with baseline A1C >= 7.5% had time above range (TAR, >180 mg/dL) that reduced from 31.6% to 20.8%. Auto Mode use also increased the percentage achieving combined recommendations for time at sensor glucose ranges (i.e., TIR of >70%, TBR of <4% and TAR of <25%) from 24.2% at baseline to 77.4% at study end. Total daily insulin dose reduced from 42.8 +/- 19.8 to 40.7 +/- 18.9 U (P = 0.013). There were no severe hypoglycemic, DKA, or serious adverse events.Conclusions: Chinese adolescents and adults, some of whom met target A1C at baseline, safely achieved significantly improved glycemia with 1 month of MiniMed 770G system use when compared to open-loop insulin delivery. ClinicalTrials.gov ID: NCT04663295.

Waitzkin Responds.

Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial

Tobacco use and nasopharyngeal carcinoma in a cohort of us veterans

Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol

Study protocol for a randomised open-label clinical trial examining the safety and efficacy of the Android Artificial Pancreas System (AAPS) with advanced bolus-free features in adults with type 1 diabetes: the 'CLOSE IT (Closed Loop Open SourcE In Type 1 diabetes) trial

Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial

Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial

Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes

Neptus - a framework to support multiple vehicle operation

Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial

Effectiveness of a structured educational intervention using psychological delivery methods in children and adolescents with poorly controlled type 1 diabetes: a cluster-randomized controlled trial of the CASCADE intervention

Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.

The JDRF CCTN CGM TIME Trial: Timing of Initiation of continuous glucose Monitoring in Established pediatric type 1 diabetes: study protocol, recruitment and baseline characteristics

Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring

Parental perspectives following the implementation of advanced hybrid closed‐loop therapy in children and adolescents with type 1 diabetes and elevated glycaemia

[An eye wound that led to the death of a king in the wedding of Philip II and Elizabeth of Valois].

Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies

A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes

Automated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1c

Lived Experience of Fully Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes

Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus